You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Discovery of therapeutic nanobodies targeting brain TNF-α for the treatment of Alzheimer Disease

    SBC: NANONEWRON LLC            Topic: NIA

    Project SummarySporadic, late onset Alzheimer disease (LOAD) is the most common form of aging-dependent neurodegenerative disorder. LOAD is associated with deposition of extracellular amyloid plaques and intra-neuronal neurofibrillary tangles (NFT), formed by Aβ peptides and phosphor- tau, respectively, in the central nervous system (CNS). Although there is strong consensus that toxic forms of AΠ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer

    SBC: MIRIMUS INC            Topic: NCI

    Abstract Colorectal cancer (CRC) is the third most diagnosed cancer in the USA and accounts for more than 600,000 deaths annually worldwide, primarily due to relapse with highly aggressive, chemo-resistant disease characterized by poorly differentiated cancer cells with stem cell-like properties. A common signature of these chemo-resistant tumors is dysregulation of Notch receptor signaling, as we ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. CELL EXPANSION BIOREACTORS FOR ASSAY-READY IMMUNOCOMPETENT PATIENT MODELS

    SBC: Link Biosystems Inc.            Topic: 102

    Project Summary/Abstract Although cancer is a leading cause of death globally, oncology drugs have the lowest success rates, cost the most to develop, and constantly show promising results in animals and then fail to work in patients. Thus, there is a need for models that facilitate understanding of how a drug will work in humans and for specific patient populations. The availability of human tumo ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Nicotinamide-Riboside plus Pterostilbene as a Disease Modifying Osteoarthritis Therapeutic

    SBC: Elysium Health, Inc.            Topic: NIAMS

    Osteoarthritis is a progressive joint disease that affects more than 32 million Americans and over 655 million worldwide. OA is the leading cause for pain and disability in individuals over 65. Estimates place the annual US economic burden of OA at $136.4 billion. OA care continues to rely on NSAIDS for symptomatic pain management and joint replacement as a last-resort. Disease modifying OA therap ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Endoscopy-assisted intracochlear access via ultrasharp-microneedles

    SBC: HAYSTACK MEDICAL, INC.            Topic: NIDCD

    PROJECT SUMMARY / ABSTRACT Up to 2.5 billion people worldwide will suffer from hearing loss or balance disorders by 2050, with a significant portion having underlying causes in the inner ear. This includes hearing loss due to age, noise and medications as well as various balance disorders, which in total afflicts approximately one in three people between the ages of 65 and 751. Atraumatic medical ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes

    SBC: POP Biotechnologies Inc.            Topic: NIA

    Project Summary/Abstract Alzheimer’s disease (AD) currently affects ~6.2 million Americans, and this number is projected to increase to 14 million by 2060 unless novel treatments or interventions to prevent or delay the onset of AD are identified. Harnessing the immune system to prevent or remove Aβ and/or tau pathologies represents a promising disease- modifying therapeutic approach for the tr ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Live spike sorting for multichannel and high-channel recordings

    SBC: POPNEURON LLC            Topic: 106

    Project Summary: The goal of this project is to create two prototypes of a novel live spike sorting system which can be used by investigators to spike sort streams of neural data recorded by multi-channel, high channel and ultra-high channel probes. In most in-vivo extracellular recording conditions, an electrode can pick up neural spikes from several nearby neurons resulting in so-called “multi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. The development of the Clinical Picture Maker, a novel video platform to aid the diagnosis and treatment of SCN2A-related disorders, and other rare diseases.

    SBC: Tiranoff Productions LLC/GeneticaLens            Topic: 100

    ABSTRACT This STTR application proposes a new platform, the Clinical Picture Maker, which aims to facilitate the production, organization, and dissemination of video documentation that can improve the diagnosis and treatment of rare and difficult to diagnose disorders. At present, people with rare disorders and their caregivers often face a 5+ year search for a diagnosis, which can lead to serious ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. IgE-suppressing small molecule compound Xanthopurpurin analog for multiple food allergies

    SBC: GENERAL NUTRACEUTICAL TECHNOLOGY LLC            Topic: NIAID

    Food allergy (FA), a potentially life-threatening condition, has rapidly increased for 2 decades, affecting 32 million Americans with annual costs of $25 billion. Treatment options are extremely limited. Food avoidance and rescue medication after accidental exposure are primary to FA management. Peanut allergy (PNA) causes severe reactions, often co-existing with tree nut allergies (TNA). Shellfis ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Innovative medical device to treat nonunion fracture for older adults

    SBC: WNT SCIENTIFIC LLC            Topic: NIA

    AbstractBony fracture is one of the most challenging musculoskeletal injuries in the elderly population. In clinic, a significant decline in bone healing potential, accompanying with mental and life- threatening complications, is commonly observed in elderly who are 65 years or older. With the rapid growth of elderly population in the US, it imposes a substantial cost burden on the health care sys ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government